OverviewSuggest Edit

Mylan is a global pharmaceutical company, which develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals. It operates in two segments: Generics and Specialty. The company manufactures and sells a portfolio of injectable products across various therapeutic areas. Mylan markets its products to wholesalers, distributors, retail pharmacy chains, group purchasing organizations, government entities, independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan combined with Upjohn to form Viatris, a new healthcare company.

StateClosed
TypePublic
Founded1961
HQCanonsburg, PA, US
Websitemylan.com
Employee Ratings3.6
Overall CultureA

Latest Updates

Employees (est.) (Dec 2019)35,000
Revenue (FY, 2019)$11.5 B
Share Price (Jan 2021)$17.2(+2%)
Cybersecurity ratingDMore

Key People/Management at Mylan

Heather Bresch

Heather Bresch

Chief Executive Officer, Executive Director
Robert J. Coury

Robert J. Coury

Executive Chairman, Executive Director
Rajiv Malik

Rajiv Malik

President, Executive Director
Robert Cindrich

Robert Cindrich

Non-Executive Director
Anthony Mauro

Anthony Mauro

Chief Commercial Officer
JoEllen Lyons Dillon

JoEllen Lyons Dillon

Non-Executive Director
Show more

Mylan Office Locations

Mylan has offices in Canonsburg and Hatfield
Canonsburg, PA, US (HQ)
1000 Mylan Boulevard
Hatfield, GB
Building 4, trident place, Mosquito Way
Show all (2)

Mylan Financials and Metrics

Mylan Revenue

Embed Graph
View revenue for all periods
Mylan's revenue was reported to be $11.5 b in FY, 2019 which is a 0.6% increase from the previous period.
USD

Revenue (Q3, 2020)

3.0b

Gross profit (Q3, 2020)

1.2b

Gross profit margin (Q3, 2020), %

39%

Net income (Q3, 2020)

185.7m

EBIT (Q3, 2020)

351.4m

Market capitalization (28-Jan-2021)

8.6b

Closing stock price (28-Jan-2021)

17.2

Cash (30-Sept-2020)

664.5m

EV

20.3b
Mylan's current market capitalization is $8.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

11.9b11.4b11.5b

Revenue growth, %

(4%)1%

Cost of goods sold

7.1b7.4b7.6b

Gross profit

4.8b4.0b3.9b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.7b2.8b2.9b2.5b2.9b3.0b2.6b2.7b3.0b

Cost of goods sold

1.7b1.8b1.8b1.7b1.9b1.9b1.7b1.7b1.8b

Gross profit

984.3m962.5m1.0b805.2m932.6m1.1b906.1m1.0b1.2b

Gross profit Margin, %

37%34%36%32%33%36%35%38%39%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

292.1m388.1m475.6m

Accounts Receivable

3.6b2.9b3.1b

Prepaid Expenses

766.1m518.4m552.0m

Inventories

2.5b2.6b2.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

367.4m330.2m449.2m229.8m211.5m358.9m572.4m323.6m664.5m

Accounts Receivable

3.0b2.8b2.9b2.8b2.7b2.9b2.8b2.8b3.0b

Prepaid Expenses

728.0m588.4m583.2m545.2m573.9m574.7m613.9m602.1m684.1m

Inventories

2.6b2.6b2.6b2.7b2.8b2.8b2.6b2.8b3.0b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

696.0m352.5m16.8m

Depreciation and Amortization

1.8b2.1b2.0b

Inventories

(129.5m)(547.6m)(512.9m)

Accounts Payable

14.4m220.3m(96.3m)
USDFY, 2017

EV/EBIT

25.8 x

EV/CFO

18 x

Revenue/Employee

340.2k

Debt/Equity

1.1 x

Debt/Assets

0.4 x

Financial Leverage

2.7 x

P/E Ratio

32.5
Show all financial metrics

Mylan Operating Metrics

FY, 2017FY, 2018FY, 2019

Products

7.5 k7.5 k7.5 k

Countries

165165165

Products (Cardiovascular)

1.15 k1.15 k

Products (Dermatology)

500500
Show all operating metrics

Mylan Acquisitions / Subsidiaries

Company NameDateDeal Size
Renaissance Acquisition HoldingsMay 13, 2016$950 m
MedaFebruary 10, 2016$7.2 b
Abbott LaboratoriesJuly 14, 2014$5.3 b
Agila SpecialtiesDecember 06, 2013$1.8 b
Bioniche Pharma Holdings LimitedSeptember 07, 2010
Merck GenericsMay 12, 2007$6.7 b
Matrix LaboratoriesAugust 28, 2006
King PharmaceuticalsJuly 26, 2004
PenedermJune 29, 1998$205 m
Abbex AB
Show more

Mylan Revenue Breakdown

Embed Graph

Mylan revenue breakdown by business segment: 16.0% from Central Nervous System & Anesthesia, 14.5% from Infectious Disease, 15.9% from Respiratory & Allergy, 7.8% from Cardiovascular, 10.0% from Gastroenterology, 7.3% from Diabetes & Metabolism, 6.3% from Women’s Health, 9.2% from Oncology and 13.0% from Other

Mylan revenue breakdown by geographic segment: 27.9% from Rest of World, 36.6% from North America and 35.5% from Europe

Show all human capital metrics

Mylan Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

SecurityScorecard logo

Mylan Online and Social Media Presence

Embed Graph

Mylan Company Culture

  • Overall Culture

    A

    75/100

  • CEO Rating

    B

    70/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Mylan News and Updates

FTC Approves Final Order Imposing Conditions on Combination of Pfizer Inc.s Upjohn and Mylan N.V.

Following a public comment period, the Federal Trade Commission has approved a final order   settling charges that the combination of the Upjohn division of pharmaceutical company Pfizer and Mylan N.V. would violate federal antitrust law.read more

Mylan's Morgantown plant shutting down as part of new company's restructuring plan

Viatris — the new company formed through the merger of Mylan and Upjohn — announced Friday that Mylan’s flagship pharmaceuticals plant in Morgantown, W.Va., is on the chopping block as part of the company’s restructuring plan aimed at slashing at least $1 billion in costs by the end of 2024

USW Aims to Mitigate Effects of Planned Shutdown at Mylan

MORGANTOWN, W.Va., Dec. 11, 2020 /PRNewswire/ -- The United Steelworkers (USW) released the following statement today from USW District 8 Director Ernest R. "Billy" Thompson in response to the announcement that Mylan owner Viatris plans to close the company's manufacturing facility in...

Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.

HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and nine months ended September 30, 2020. Third Quarter 2020 Financial Highlights Total revenues of $2.97 billion, a slight increase on an...

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski, CFA, has joined the company as Head of Capital Markets, in a new leadership role working closely with senior leadership. He will be serving in that same capacity for VIATRISTM ("Viatris"

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the "FTC") accepted a proposed consent order, which concludes the FTC's review of the proposed combination of Mylan and Pfizer's Upjohn Business. The parties have now obtained all required an…
Show more

Mylan Blogs

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski , CFA, has joined the company as Head of Capital Markets, in a new leadership role working closely with senior leadership.

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn Liz.McPherson@… Fri, 10/30/2020 - 13:22 Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn …

Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn

The Companies Have Also Received Approvals in Australia and New Zealand; Combination on Track to Close in Fourth Quarter 2020

Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn

The Companies Have Also Received Approvals in Australia and New Zealand; Combination on Track to Close in Fourth Quarter 2020 HERTFORDSHIRE, England , PITTSBURGH and NEW YORK , Sept. 15, 2020 /PRNewswire/ --  Mylan   (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the companies have
Show more

Mylan Frequently Asked Questions

  • When was Mylan founded?

    Mylan was founded in 1961.

  • Who are Mylan key executives?

    Mylan's key executives are Heather Bresch, Robert J. Coury and Rajiv Malik.

  • How many employees does Mylan have?

    Mylan has 35,000 employees.

  • What is Mylan revenue?

    Latest Mylan annual revenue is $11.5 b.

  • What is Mylan revenue per employee?

    Latest Mylan revenue per employee is $328.6 k.

  • Who are Mylan competitors?

    Competitors of Mylan include Amgen, BioMarin Pharmaceutical and Cipla.

  • Where is Mylan headquarters?

    Mylan headquarters is located at 1000 Mylan Boulevard, Canonsburg.

  • Where are Mylan offices?

    Mylan has offices in Canonsburg and Hatfield.

  • How many offices does Mylan have?

    Mylan has 2 offices.